Information Provided By:
Fly News Breaks for May 30, 2018
LLY, INCY
May 30, 2018 | 16:10 EDT
Piper Jaffray analyst Tyler Van Buren assumed coverage of Incyte (INCY) with an Overweight rating and $85 price target, stating that he expects Jakafi to produce durable, high-margin revenues approaching $2.5-$3B over the next ten years and predicts Incyte and partner Lilly (LLY) will receive an approval for baricitinib next week.